Loading...
Docoh

Bausch Health Companies (BHC)

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health.

Company profile

Ticker
BHC
Exchange
CEO
J. Michael Pearson
Employees
Incorporated
Location
Fiscal year end
Former names
BIOVAIL Corp, BIOVAIL CORP INTERNATIONAL, BIOVAIL CORPORATION INTERNATIONAL, Valeant Pharmaceuticals International, Inc.
SEC CIK
Subsidiaries
Bausch & Lomb Argentina S.R.L. • Waicon Vision S.A. • Bausch & Lomb (Australia) Pty Limited • Bausch Health Australia Pty Limited • Wirra Holdings Pty Limited • Bausch & Lomb Australia Holdings Pty Limited • Solta Medical Australia Pty Limited • BAUSCH HEALTH LLC • Bausch & Lomb Pharma S.A. • PharmaSwiss BH Društvo za trgovinu na veliko d.o.o. ...

BHC stock data

Analyst ratings and price targets

Last 3 months

Calendar

10 May 22
12 Aug 22
31 Dec 22
Quarter (USD) Mar 22 Dec 21 Sep 21 Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 2.46B 2.46B 2.46B 2.46B 2.46B 2.46B
Cash burn (monthly) (no burn) (no burn) (no burn) (no burn) 21M (no burn)
Cash used (since last report) n/a n/a n/a n/a 92.4M n/a
Cash remaining n/a n/a n/a n/a 2.37B n/a
Runway (months of cash) n/a n/a n/a n/a 112.7 n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
30 Jun 22 Schutter Richard U De Common Shares, No Par Value Grant Acquire A No No 8.36 4,111 34.37K 359,590
30 Jun 22 Brett Icahn Common Shares, No Par Value Grant Acquire A No No 8.36 3,663 30.62K 51,157
30 Jun 22 Steven D Miller Common Shares, No Par Value Grant Acquire A No No 8.36 3,663 30.62K 101,279
30 Jun 22 Wechsler Amy B Common Shares, No Par Value Grant Acquire A No No 8.36 822 6.87K 134,563
30 Jun 22 Robertson Russel C Common Shares, No Par Value Grant Acquire A No No 8.36 4,560 38.12K 167,200
0.4% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 2 2
Opened positions 0 0
Closed positions 0 1 EXIT
Increased positions 0 0
Reduced positions 1 0 NEW
13F shares Current Prev Q Change
Total value 31.84M 38.48M -17.3%
Total shares 1.39M 1.39M -0.0%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners Shares Value Change
Bruce & Co. 1.38M $31.56M 0.0%
LeJeune Puetz Investment Counsel 12.39K $283K -2.9%
Largest transactions Shares Bought/sold Change
LeJeune Puetz Investment Counsel 12.39K -364 -2.9%
Bruce & Co. 1.38M 0 0.0%

Financial report summary

?
Risks
  • As a result of the current conflict between Russia and Ukraine, including the recent invasion of Ukraine by Russia, the current and any future responses by the global community to such conflict and any counter responses by the Russian government or other entities or individuals, and the potential expansion of the conflict to other countries, we have begun to experience and may continue to experience an adverse impact on our business and operations in this region, as well as on our business and operations generally, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares to decline.
Management Discussion
  • Revenues for 2021 and 2020 were $8,434 million and $8,027 million, respectively, an increase of $407 million, or 5%. The increase was primarily driven by: (i) a net increase in volumes and (ii) the favorable impact of foreign currencies, primarily in Europe, Asia and Canada. These increases were partially offset by: (i) our divestiture of Amoun on July 26, 2021 and (ii) a decrease in net realized pricing. The net increase in volumes was primarily due to the positive impacts from the recovery from the COVID-19 pandemic and the easing of certain social restrictions, as previously discussed, primarily during the three months ended June 30, 2021, partially offset by the impact of the loss of exclusivity of certain products. The changes in our segment revenues and segment profits are discussed in further detail in the subsequent section titled “Reportable Segment Revenues and Profits”.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: abeyance, affiliate, agricultural, Apotex, banc, bankruptcy, benchmark, BLCO, bromide, buy, Cal, CDOR, cease, chapter, closer, CODM, commodity, community, conference, counter, counteractive, cyber, cybersecurity, cyberterrorism, Czech, damage, dealt, Dexamethasone, disconnect, discontent, displacement, divisional, doubt, Dutch, en, energy, EU, EURIBOR, exacerbating, facilitate, faith, fleeing, flexibility, Flunisolide, gas, gave, geopolitical, hampered, hepatology, hinder, hryvnia, humanitarian, IG, imposition, inadequate, inception, increasingly, installation, installment, Interntaional, invaded, invasion, Irish, irrevocably, JJCI, knowledge, Latanoprost, LIBOR, LTL, Lupin, mediate, mediation, Mellon, merger, methynaltrexone, military, network, notch, Notwithstanding, oil, omicron, overseeing, perpetrated, piped, popular, practice, precise, preclude, proactively, promptly, protracted, provoked, refundable, registration, rehearing, Remainco, repatriation, reply, Republic, retaliatory, ruble, Russia, Russian, satisfaction, Shanghai, shelter, sixty, skincare, Slovakia, SOFR, solicitation, Somerset, SONIA, StableVisc, sterling, stoppage, substantive, subvariant, surge, suspend, suspended, talc, taxation, thereunder, ticker, Tobramycin, traffic, trail, transitional, trustee, UK, Ukraine, Ukrainian, unavailability, underwriting, undrawn, unforeseen, Uniform, unrestricted, unwind, unwinding, unwound, vii, viii, voidable, war, Western, WHA, wholly, wider, worse, worsen
Removed: accessed, actinic, adenylate, Adjudication, Allegro, anemia, angiogenic, antihistamine, appointed, Appointment, ASS, atopic, bill, biopharmaceutical, Bisocard, bolt, bottom, BP, calculating, channel, classified, combined, commencement, complexity, compliant, consumption, Contrave, cyclase, defer, Departure, derivative, developing, Diastat, distributing, doctor, duty, Espaven, Eton, evidence, exceed, expanding, expensed, expensive, experiencing, exploring, FASB, fatty, feet, fiduciary, field, financed, forced, fumarate, funding, gradual, Graham, greatest, hiring, home, House, idling, impactful, implicated, initiation, insulated, integrin, interaction, intraperiod, Italy, Ivexterm, Jan, ketotifen, launching, led, Los, Luminate, measuring, metabolic, methodology, metric, Milan, minimizing, mitochondrial, moving, Mysimba, NAFLD, NASH, necessitate, NeutraSal, nonalcoholic, notably, operation, Ophtho, originated, performing, pituitary, postponement, postponing, preferred, prepay, preservative, prioritization, prioritize, privately, progressed, Prolensa, promoted, purportedly, readily, realigned, rebalancing, reenacting, relieve, remained, reopening, responded, retina, revising, risuteganib, room, separately, simultaneously, site, slower, spot, statue, steeper, Stockholder, targeting, thirty, Thrombo, translate, travel, unfavorably, University, VBP, Vice, warning, waste, yield

Patents

Utility
Water Extractable Ophthalmic Devices
11 Aug 22
A water extractable ophthalmic device is disclosed which is a polymerization product of a monomeric mixture comprising: (a) one or more cyclic lactams; (b) one or more non-bulky organosilicon-containing monomers; (c) one or more bulky siloxane monomers; and (d) a crosslinking agent mixture comprising (i) one or more first crosslinking agents containing at least two ethylenically unsaturated reactive end groups, wherein the at least two ethylenically unsaturated reactive end groups are (meth)acrylate-containing reactive end groups and (ii) one or more second crosslinking agents containing at least two ethylenically unsaturated reactive end groups wherein at least one of the ethylenically unsaturated reactive end groups is a non-(meth)acrylate reactive end group.
Design
Access device
2 Aug 22
Inventors: Craig Bockenstedt, Richard Malwitz, Adam Weisgerber, Jeffrey Ladwig, Aaron Piazza, Michael Carl Beckman
Utility
Encrypted memory device
2 Aug 22
In one implementation, a system for detecting counterfeit accessories that are consumable, disposable, or otherwise user replaceable is disclosed.
Utility
Topical Compositions and Methods for Treating Skin Diseases
28 Jul 22
Topical pharmaceutical compositions include tazarotene or a pharmaceutically acceptable salt of tazarotenic acid and an oil-in-water emulsion vehicle that forms a lotion.
Design
Light therapy device
26 Jul 22
Inventors: Craig Bockenstedt, Richard Malwitz, Adam Weisgerber, Jeffrey Ladwig, Aaron Piazza, Michael Carl Beckman